VAL 0417
/ Valerion
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 07, 2023
Perturbed glycogen metabolism is an Alzheimer's disease therapeutic target
(AAIC 2023)
- "Multiple agents can decrease Aβ and tau levels, such as the recently FDA-approved Aducanumab. These studies suggest that targeting AD glycogen with VAL-0417, either alone or in combination with other therapies targeting Aβ and/or tau, is an exciting and novel preclinical therapeutic target."
Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia
1 to 1
Of
1
Go to page
1